康方生物,别以为你稳了

医曜
Nov 10, 2025

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。康方生物与三生制药,两家本无交集的药企,却因PD-1/VEGF靶点而成为直接对手。2025年10月30日,辉瑞宣布启动与三生制药合作的PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验,分别针对晚期非小细胞肺癌和转移性结直肠癌的一线治疗,标志着该双抗正式进入全球确证性临床阶段。就在同一天,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10